The pill doesn’t have the fasting requirements of many other weight loss drugs

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B obesity franchise.

An experimental daily weight loss pill helped people shift more than ten per cent of their bodyweight after six months, research has found.

Especialistas consideran que el medicamento merece evaluaciones más amplias antes de solicitar su autorización

Doentes perderam 10,5% do peso em 26 semanas num ensaio intermédio da pílula experimental da AstraZeneca, que quer disputar o mercado do emagrecimento com a Novo Nordisk e a Eli…

A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other GLP-1 oral drugs, trial results showed Monday.

Investigational pill was well-tolerated and doesn't come with food or water restrictions

AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.

The pill doesn’t have the fasting requirements of many other weight loss drugs

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…